{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095417","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.105487+00:00","generated_at":"2026-05-31T10:04:42.320621+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spruce Biosciences Q2 net loss $9.2M; cash $69.7M; MDD collaboration with HMNC","bullets":["Net loss $9.2M for Q2 2024 vs $12.8M in Q2 2023; operating expenses down to $11.6M.","Cash $69.7M as of June 30, 2024, expected to fund operations through end of 2025.","Entered collaboration with HMNC to develop tildacerfont for major depressive disorder; HMNC funds Phase 2 study.","Topline data from CAHmelia-204 and CAHptain-205 trials expected in Q4 2024.","Collaboration revenue $1.6M from Kaken agreement, down from $2.2M in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095417","json":"https://secwatch.observer/filing/0000950170-24-095417.json","markdown":"https://secwatch.observer/filing/0000950170-24-095417.md","text":"https://secwatch.observer/filing/0000950170-24-095417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024095417/0000950170-24-095417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024095417/sprb-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:04:42.320621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}